News ReleaseView printer-friendly version
Quidel Corporation to Present at the 28th Annual J.P. Morgan Healthcare Conference
A live webcast and audio archive of the 30-minute presentation will be available via the Investor Relations section of Quidel's Web site at http://www.quidel.com. During the presentation, the company will discuss business and financial developments and trends. The company's statements may contain or constitute material information that has not been previously disclosed. Listeners should allow approximately five to ten minutes prior to the presentation start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will be available on Quidel's Web site for 14 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point-of-care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue(R), Quidel's portfolio of products currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, respiratory syncytial virus, Fecal Occult Blood, Strep A, pregnancy, H. pylori and Chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment have an impact on clinical outcomes and provide an economic benefit. For more information, visit http://www.quidel.com, http://www.colorectal-test.com, www.rsvtesting.com and http://www.flutest.com.
SOURCE: Quidel Corporation
John M. Radak, Chief Financial Officer
Media and Investors Contact:
Porter Novelli Life Sciences
Pam Lord, 619-849-6003